Physician profile
Brian Holmes
NPI 1457371809
$3,055.09
in general payments reported to CMS, 2019-2025
27 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $436 · 2021: $272 · 2022: $457 · 2023: $385 · 2024: $310 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $810.30 | 2021-2025 | Rialto Si Fusion System, Inceptiv, Cd Horizon Spinal System |
| Abbott Laboratories | $474.60 | 2019-2024 | Proclaim, Eterna |
| Globus Medical, INC. | $362.79 | 2019-2021 | |
| Medtronic USA, INC. | $208.10 | 2019-2020 | |
| Boston Scientific Corporation | $164.97 | 2019-2020 | |
| Si-Bone, INC. | $161.01 | 2019-2025 | |
| Csl Behring | $142.16 | 2019-2020 | |
| Providence Medical Technology, INC. | $134.20 | 2021-2022 | |
| Intrinsic Therapeutics | $92.30 | 2023-2025 | Barricaid Acd (Annular Closure Device) |
| Pacira Therapeutics, INC. | $81.65 | 2019 | |
| Stryker Corporation | $48.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.31 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.24 | 2019-2020 | |
| Kuros Biosciences USA, INC | $39.18 | 2023 | |
| Saluda Medical Americas, INC. | $38.85 | 2024 | Evoke |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Precision Spine, INC. | $20.98 | 2019 | |
| Mdd US Operations, LLC | $20.89 | 2020 | |
| Lilly USA, LLC | $20.66 | 2023 | Emgality |
| Greenwich Biosciences, INC. | $18.97 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $18.57 | 2021 | |
| Ucb, INC. | $18.24 | 2020 | |
| Merck Sharp & Dohme LLC | $18.09 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.36 | 2020 | |
| Zimmer Biomet Holdings, INC. | $16.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.10 | 2020 | |
| Ibsa Pharma INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.